Alfuzosin: A review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia

Drugs

Volumn 62, Issue 4, 2002, Pages 633-653

  McKeage, Kate ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Alfuzosin; Benign prostatic hyperplasia; Pharmacodynamics; Pharmacokinetics; Therapeutic use

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; PRAZOSIN; QUINAZOLINE DERIVATIVE; TAMSULOSIN; TERAZOSIN;

ANGINA PECTORIS; AREA UNDER THE CURVE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG TOLERABILITY; EJACULATION; FIRST PASS EFFECT; HUMAN; MALE; ORTHOSTATIC HYPOTENSION; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEXUAL FUNCTION; SUSTAINED RELEASE FORMULATION; SYMPTOM; URINE FLOW RATE; VASODILATATION;

ANGINA;

EID: 0036210668     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262040-00009     Document Type: Review

References (52)

1. Benign prostatic hyperplasia: Choosing the best therapy for each patient
2. Medical therapy for benign prostatic hyperplasia: A review of the literature
3. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia
4. Benign prostatic hyperplasia
5. Benign prostatic hyperplasia: Practical treatment guidelines
6. 1C subtype
7. 1-adrenoceptor antagonists for the treatment of benign prostatic hyperplasia
8. Alfuzosin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia
9. 1-adrenoceptor antagonist in the lower urinary tract
10. 1-adrenoceptor antagonist effects of alfuzosin in rabbit and dog lower urinary tract
11. In vivo uroselectivity of alfuzosin compared to prazosin and terazosin
12. Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations
13. Orally administered alfuzosin (ALF) has a high prostatic diffusion in benign prostatic hyperplasia tissue
14. Prostate selectivity of alpha 1 adrenoceptor blockers
15. Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists
16. Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin
17. Alfuzosin for treatment of benign prostatic hypertrophy
18. 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia
19. Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin
20. Medical therapy for benign prostatic hyperplasia
21. Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate
22. Alpha blockers: Are all created equal?
23. 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery
24. 1-adrenoceptor subtype-specific blockade
25. 1 adrenoceptors: Binding, functional and in vivo studies
26. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia
27. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Pooled analysis of eleven controlled studies with alfuzosin
28. Sustained-release alfuzosin and trial without catheter after acute urinary retention: A prospective, placebo-controlled trial
29. Bioequivalence of a new once-a-day controlled-release alfuzosin formulation with the immediate-release alfuzosin
30. Bioequivalence study of a new once-a-day controlled-release alfuzosin formulation with the 5 mg twice daily formulation
31. Safety and pharmacokinetics of alfuzosin 10 mg once daily formulation comparatively to standard formulation (2.5 mg tid) in elderly subjects
32. Effect of renal impairment on the pharmacokinetics and safety of alfuzosin 10 mg OD formulation
33. Synthelabo. Xatral (alfuzosin 10 mg) once daily
34. Long-term treatment of benign prostatic hyperplasia with alfuzosin: A 12-18 month assessment
35. Long-term treatment of benign prostatic hyperplasia with alfuzosin: A 24-30 month survey
36. Alfuzosin in the treatment of benign prostatic hyperplasia: Effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial
37. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-Year results
38. Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in general practice
39. Long-term quality of life in patients with benign prostatic hypertrophy: Preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin
40. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia
41. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia
42. Efficacy and safety of once daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A randomized, placebo-controlled trial
43. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: Open label extension study
44. The American Urological Association symptom index for benign prostatic hyperplasia
45. Symptom indices and quality-of-life questionnaires for use in benign prostatic hyperplasia
46. Sanofi-Synthelabo
47. Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia
48. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia
49. Finasteride: An update of its use in the management of symptomatic benign prostatic hyperplasia
50. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
51. Future concepts in the medical therapy of benign prostatic hyperplasia